ZEAL&
Home
Twitter
Search
About Zealand
Strategy and Business model
Purpose, Mission and Values
Board of Directors and Executive Management
History
Careers
Fact sheet and Corporate presentation
Image bank
Pipeline
Drug candidates for diabetes and metabolic diseases
Drug candidates for gastro-intestinal diseases
Drug candidates for cardiovascular diseases
R&D
Key Zealand peptide competences
Therapeutic focus areas
Scientific Advisory Board
IP
Partnering
Our partnering strategy
License and development partnerships
Peptide drug discovery collaborations
Business Development
Investors
News
Events & Presentations
Stock information
Financial Reports
Annual General Meeting
Corporate Governance
Corporate social responsibility
IR
Shareholder portal
Contact
Driving Instructions
Lyxumia® (Lixisenatide)
ZP2929
Elsiglutide
ZP1848
Danegaptide (ZP1609)
ZP1480 (ABT-719)
